literature

HIV mutation literature information.

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.

PMID: 34871089 2022 Antimicrobial agents and chemotherapy

Method: Patients with previously documented HIV-2 infection, with active AIDS, and with documented genotypic evidence of >=1 NNRTI resistance-associated mutation (RAM) from a predefined list of the following NNRTI RAMs at screening were excluded: A98G, L100I, K101E, K101P, K101Q, K103H, K103N, K103S, K103T, V106A, V106M, V108I, E138A, E138G,

HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.

PMID: 34762770 2021 Journal of the International AIDS Society

Table: K238T/N

HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naive HIV-infected individuals.

PMID: 32119691 2020 PloS one

Table: K238T/N

The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017.

PMID: 33347449 2020 PloS one

Abstract: 48 DRMs were identified from 43 samples, indicating a drug resistance prevalence of 12.1% (43/356), which include seven protease inhibitors (PIs) accessory DRMs (Q58E, L23I and

Result: We analyzed the following specific DRMs: 1) 66.7% (32/48) DRMs were on nonnucleoside reverse transcriptase inhibitors (NNRTIs) as: V179E (n = 12), E138A (n = 4), Y188D (n = 1), K103N (n = 2), A98G (n = 1), K238N (n = 2), V179D (n = 8), E138G (n = 1), G190E (n = 1).

The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012-2014.

PMID: 28622345 2017 PloS one

Result: 31 specific DRMs were identified from 27 samples with DRMs distributing as: 1) 74.2% (23/31) DRMs were on nonnucleoside reverse transcriptase inhibitors (NNRTIs) as: V179E/D (n = 16), K238N (n = 2), E138A/G (n = 4) and G190E (n = 1).

Table: K238N

Discussion: Drug-specific NNRTIs mutations such as: V179E, K238N and G190E were associated with the selection in patients receiving Nevirapine (NVP) and Efavirenz (EFV) according to Stanford HIVdb program.

Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY(R) System.

PMID: 27092551 2016 PloS one

Table: K238N

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.

PMID: 27120449 2016 PloS one

Method: RT-RAMs were identified and analyzed by using the Stanford Drug Resistance Database for V90I, A98G, L100I/V, K101E/P/Q/H/N, K103N/S/T/Q/E/H/R, V106A/M/I, V108I, E138A/K/Q/G/R, V179D/E/T/F/L, Y181C/I/V/S/F/G, M184I, Y188C/H/L/F, G190A/S/E/Q/C/V/T, H221Y,

HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.

PMID: 26558396 2015 PloS one

Table: K238N

Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.

PMID: 25006528 2014 ISRN AIDS

Discussion: Of these secondary mutations P225H (1/19) & K238T/N (2/19) were the secondary NNRTI mutation seen in our study.

Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro.

PMID: 22984494 2012 PloS one

Result: In these combination pr

Result: Similarly, the variants with additional K238N/T48I/I178M, I178M/I382V and I135T/I382L resulted in about 10, 3.5 and 7.3 folds increase of NVP resistance, respectively.

Table: K238N

Browser Board

Co-occurred Entities

Filtrator